anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In the present invention, there is disclosed an immunogenic polypeptide comprising an amino acid sequence consisting of residues 2 to 710 of SEQ ID NO: 16 (Figure Nos. 8A and 8B) wherein said amino acid sequence optionally comprises one amino acid deletion and/or substitution and is optionally free of histidine residues at its N-terminal end. There is also disclosed a polynucleotide comprising a nucleotide sequence encoding the said polypeptide. In another embodiment there is a polynucleotide comprising a first nucleotide sequence, which hybridizes under slight stringent conditions or very stringent conditions with a second nucleotide sequence being complementary to a third nucleotide sequence encoding the residues 2 to 710 of the amino acid sequence SEQ ID NO: 16 (Figure Nos. 8A and 8B), optionally without bonds of histidine residues at N-terminal end wherein said polynucleotide comprises a first nucleotide sequence, which encodes the immunogenic polypeptide being functionally equivalent to the residues 2 through 710 of the amino acid sequence SEQ ID NO: 16, optionally without bonds of histidine residues at N-terminal end, in the proliferation test of T cells or in the interferon gamma production test. The invention also relates to a polypeptide encoded by this aforementioned polynucleotide and a pharmaceutical composition containing said polypeptide or said polynucleotide. Other subjects of the present invention are an expression vector containing said polypeptide and a vaccine containing said polypeptide or said polynucleotide. There is also described an isolated host cell, which recombinantly expresses said polynucleotide. Finally, the invention relates to a process for preparing the polypeptide comprising recombinant expression of the aforementioned polynucleotide.
PURPOSE:To prevent the dislodgment and failure of the artificial root of tooth by constituting the front ends of the roots of tooth of such a shape memory alloy material which expands slightly after being implanted within the jaw bone. CONSTITUTION:Three pieces of the roots 2 are formed in the lower part of the artificial root of tooth. The entire part is produced by the shape memory alloy consisting of a TiPd-Co alloy at this time. The jaw bone is bored with cavities and the roots 2 are embedded and implanted down to the tooth neck part into a socket. Three pieces of the roots 2 expand to the previously memorized shape and the front ends of the roots 2 are fixed securely by coming into tight contact with the inside wall of the socket of the jaw bone when the roots are heated to the transformation temp. The fracture and dislodgment of the root of tooth and the destruction of the jaw bone are prevented in this way.
A solid-state hand soap concentrate formulation, comprising; i) a surfactant (such as sodium lauryl sulfate, sodium coco sulfate, ethoxylated alcohols or alkyl polyglucosides); ii) a pH control agent (such as citric acid, malic acid, sodium carbonate or sodium bicarbonate); iii) a water content of less than 5% by weight; iv) a fatty acid content of less than 10% by weight, and/or, v) an animal fat content of less than 10% by weight. The pH control agent may comprise an acidic cleaner or a basic cleaner or both. The formulation may comprise; a binding agent, a thickening agent and a preservative. The formulation may be in the form of a tablet, which preferably is non-tacky. A second aspect is directed towards a method of preparing a tablet of the composition according to the first aspect. A third aspect is directed towards a method of using the tablet according to the second aspect.
Data of 1200 eligible patients undergoing liver transplantation between July 2018 and June 2021 are selected.The sample size was randomly divided into 70% discovery set and 30% validation set according to 7:3. 70% of the discovery dataset are used for the establishment of risk prediction model. The univariate analysis is used to evaluate PI-associated risk factors. In addition, a multivariate logistic regression model is developed using selected variables and P\<0.05 in the univariate analysis is used to identify independent risk factors for PIs. The odds ratio for each independent variable is determined with a 95% confidence interval. Finally, a nomogram of predictive model is generated on the basis of the results of multivariate analysis.Discrimination capability, calibration degree, and clinical value will be used to verify the efficacy of the prediction model. This study develops and validates a prediction model for predicting the risk of PI in patients undergoing liver transplantation. Using this prediction model, we will develop decision-support systems to prevent PI in the future.
PURPOSE:To obtain an emulsion having fine particle diameters and good stability by dissolving pantothenic acid, its salts or pantothenylethyl ether in polyol, and adding oil thereto. CONSTITUTION:One or >=2 kinds selected among a group consisting of pantothenic acid, its salts and pantothenylethyl ether; watersoluble polyols having >=2 hydroxyl groups in a molecule (e.g. ethyleneglycol) and oil are incorporated to obtain an emulsified composition. Furthermore, by adding water to said composition, a stable oil in water type emulsified composition having uniform, fine emulsion particles is obtd. Since the above-described composition is a uniform, clear or translucent gel or viscous liquid, it can be used for jellies for food, cosmetics and drugs. The oil in water type emulsified composition is also an emulsion having milky fine particles, and used for cosmetics, drugs and foods.
The invention relates to an internal medicine (Shiquan powder) and an external application medicine (Shiquan ointment) for treating vasculitis and a preparation method thereof and belongs to the technical field of medicine. The internal medicine (Shiquan powder) consists of 120g of ginseng, 90g of largehead atractylode rhizome, 90g of tuckahoe, 45g of liquorice, 100g of angelica, 60g of Szechwan lovage rhizome, 100g of white peony root, 50g of prepared rehmannia root, 100g of milkvetch root, 100g of saffron, 180g of red rooted salvia root, 150g of honeysuckle, 150g of notoginseng, 150g of pangolin and 20g of muskiness. The medicines are crushed into powder and are made into powder preparation or are made into troche, pill, capsule, etc. The external application medicine (Shiquan ointment) consists of 120g of ginseng, 90g of largehead atractylode rhizome, 90g of tuckahoe, 45g of liquorice, 100g of angelica, 60g of Szechwan lovage rhizome, 100g of white peony root, 50g of prepared rehmannia root, 100g of milkvetch root, 100g of saffron, 180g of red rooted salvia root, 150g of honeysuckle, 150g of notoginseng, 150g of pangolin, 20g of muskiness, 400g of Chinese wax, 400g of beeswax and 5000g of balm. The medicines are processed by the working procedures of oil immersion, cooking, ointment collection, etc. The invention has the characteristics of supplementing qi, nourishing blood, eliminating dampness, dissolving blood stasis, detoxifying and activating meridian and treats the vasculitis by internal and external application with ideal curative effect that the total curative rate is 100 percent, the cure rate is more than 90 percent, and the invention causes no side or toxic effect after long-term use. The invention also can treat cardiovascular and cerebrovascular diseases, rheumatoid disease, osteomyelitis, hyperosteogeny, osteonecrosis, cervical spondylosis, etc.
The invention relates to application of glyceryl trioleate in preparing a medicament for preventing and/or treating related diseases mediated by an AhR-Nrf2 signal path. The medicine is used for reducing the thickness of the epidermis. The medicine is a medicine for reducing the scale content. The related diseases are atopic dermatitis, eczema or psoriasis. The dosage form of the glyceryl trioleate is a glyceryl trioleate cream, and the concentration is 5-20%. The invention adopts molecular docking to verify the binding affinity of Trilinolein and AhR. Trilinolein after a dry period, the expression levels of AhR, CYP1A1 and NRF2 proteins are obviously increased in a dose-dependent manner, and compared with a model group, the expression levels of mRNA of barrier-related proteins dsp, cdsn and loricrin are obviously increased, and the expression level of mRNA of a key medium nox2 of oxidative stress is reduced; after the AhR inhibitor is added, trilinolein is used for blocking the regulation and control effects of the terminal differentiation protein formed on the cornea and the ROS, so that the Trilinolein can play roles in skin barrier repair and antioxidation by activating the AhR-Nrf2 pathway, and a broad-prospect prevention and treatment medicament is provided for AD.
The safety and effectiveness of DERMA-SMOOTHE/FS Scalp Oil have not been established in pediatric patients with psoriasis of the scalp.

Evaluation in Peanut-Sensitive Pediatric Patients   
A clinical trial was conducted to assess the safety of the formulation of DERMA-SMOOTHE/FS Scalp Oil, which contains refined peanut oil, in patients with known peanut allergies. The trial enrolled 13 pediatric subjects with atopic dermatitis, 6 to 17 years of age. DERMA-SMOOTHE/FS Scalp Oil is not approved for the treatment of atopic dermatitis. Of the 13 subjects, 9 were Radioallergosorbent Test (RAST) positive to peanuts and 4 had no peanut sensitivity (controls). The trial evaluated the subjects’ responses to both prick test and patch test utilizing refined peanut oil, the formulation of DERMA-SMOOTHE/FS Scalp Oil and histamine/saline controls. Subjects were also treated with the formulation of DERMA-SMOOTHE/FS Scalp Oil twice daily for 7 days. Prick test and patch test results for all 13 subjects were negative to the formulation of DERMA-SMOOTHE/FS Scalp Oil and the refined peanut oil. One of the 9 peanut-sensitive subjects experienced an exacerbation of atopic dermatitis after 5 days of use on the formulation of DERMA-SMOOTHE/FS Scalp Oil.
PURPOSE: Epidural analgesia has emerged as a commonly used method for relieving labor pain. However, epidural-related maternal fever (ERMF) is characterized by a high occurrence rate and can have detrimental consequences for the well-being of both the mother and the fetus. This study aimed to investigate the functional role and underlying mechanism of dexmedetomidine (DEX) in ERMF.
MATERIALS AND METHODS: Ropivacaine (ROP)-induced human umbilical vein endothelial cells (HUVECs) were treated with DEX and/or transfected with ALKBH5 or FUNDC1 overexpression plasmid. qPCR and Western blot were adopted for mitophagy and pyroptosis marker protein detection. Autophagosomes were observed through electron microscopy, Caspase-1/PI double-positive cells were determined using flow cytometry. Inflammation-related factors were quantified using ELISA. The N6-methyladenosine (m6A) modification of FUNDC1 mRNA was examined using methylated RNA immunoprecipitation (MeRIP) and the binding between ALKBH5 and FUNDC1 mRNA was confirmed by RNA immunoprecipitation (RIP).
RESULTS: In ROP-induced HUVECs, there was a significant upregulation in ALKBH5 and FUNDC1, resulting in a notable increase in inflammation, pyroptosis, and mitophagy. The administration of DEX demonstrated the ability to alleviate ROP-induced pyroptosis and promote protective mitophagy. Interestingly, DEX treatment significantly reduced the interaction between ALKBH5 and FUNDC1 mRNA, while simultaneously increasing the m6A level of FUNDC1 mRNA in ROP-treated cells. Moreover, the overexpression of FUNDC1 partially reversed the effects of ALKBH5 overexpression on mitophagy and pyroptosis in HUVECs.
CONCLUSIONS: DEX can promote mitophagy and inhibit pyroptosis through the ALKBH5/FUNDC1 axis in ERMF, indicating its potential as a therapeutic strategy for clinical ERMF treatment.
Protein fibril surfaces tend to generate toxic oligomers catalytically. To date, efforts to study the accelerated aggregation steps involved with Alzheimer's disease-linked amyloid-β (Aβ)-42 proteins on fibril surfaces have mainly relied on fluorophore-based analytics. Here, we visualize rare secondary nucleation events on the surface of Aβ-42 fibrils from embryonic to endpoint stages using liquid-based atomic force microscopy. Nanoscale imaging supported by atomic-scale molecular simulations tracked the adsorption and proliferation of oligomeric assemblies at nonperiodically spaced catalytic sites on the fibril surface. Upon confirming that fibril edges are preferential binding sites for oligomers during embryonic stages, the secondary fibrillar size changes were quantified during the growth stages. Notably, a small population of fibrils that displayed higher surface catalytic activity was identified as superspreaders. Profiling secondary fibrils during endpoint stages revealed a nearly threefold increase in their surface corrugation, a parameter we exploit to classify fibril subpopulations.
Patients receive cixutumumab IV over 60 minutes and temsirolimus IV over 30 minutes on days 1, 8, 15, 22, 29, and 36. Courses repeat every 42 days in the absence of disease progression or unacceptable toxicity.
PURPOSE: To obtain a skin application composition containing a 7- thiaprostaglandin compound, useful as an agent for the treatment of cutaneous ulcer having the lesion part near the surface of the skin, having stability and enabling quick penetration and absorption of the main drug component through the skin. CONSTITUTION: This composition contains a compound of the formula [R<1> is a 1-10C alkyl, a 2-10C alkenyl, phenyl, etc.; R<2> is H, a 1-10C alkyl, a 2-10C alkenyl, phenyl, etc.; R<3> and R<4> are each H, a tri(1-7C hydrocarbon)silyl, etc.; R<5> is H, methyl or vinyl; R<6> is a 1-8C alkyl, a 2-8C alkenyl, a 2-8C alkenyl, etc.; (n) is 0 or 1; X-Y is ethylene, vinylene, etc.; the dotted line is double bond or single bond] as an active component at a concentration of 0.000001-1%. The composition may contain an ointment base produced by adding a paraffin or a polyethylene as a consistency modifying agent to a higher paraffinic hydrocarbon, a suspendible ointment base produced by adding an aliphatic alcohol as a consistency modifying agent to glycol or a fat ester as a solubilizing agent.  The compound of the formula has a chemotaxis inhibiting activity, an antithrombotic acid and a dermal blood flow increasing action.
NEW MATERIAL:A compound shown by formula I [R1 is H, 1-6C alkyl, benzyl or indolylcarbonyl; R2 is 5- to 8-membered heterocyclic group (may be replaced with 1-6C alkyl or arylalkyl) containing one or more N atoms; (n) is 1-5; H atom in (CH2)n may be replaced with 1-4C alkyl, phenyl and/or OH; with the proviso that a case wherein n=1 and R2 is 1-methyl-2-pyrrolidinyl or 1-benzyl-2- pyrrolidinyl is omitted] and an acid addition salt thereof. EXAMPLE:1H-Indole-3-carboxylic acid 2-(1-pyrrolidinyl)ethyl ester. USE:An antagonist selectively effective against 5-HT in 5HT3 acceptor. Effective for treating insanity, neurogenic diseases, gastrointestinal function incompetence and gastrointestinal disorder. Also effective for suppressing vomiting induced in cancer chemotherapy. PREPARATION:An indole-3-carboxylic acid shown by formula II is condensed with a compound shown by formula III to give a compound shown by formula I.
Acute exposure to hypoxia increases postural sway, but the underlying neurophysiological factors are unclear. Golgi tendon organs (GTOs), located within the musculotendinous junction (MTJ), provide inhibitory signals to plantar flexor muscles that are important for balance control; however, it is uncertain if GTO function is influenced by hypoxia. The aim of this study was to determine how normobaric hypoxia influences lower limb tendon-evoked inhibitory reflexes during upright stance. We hypothesized that tendon-evoked reflex area and duration would decrease during hypoxia, indicating less inhibition of postural muscles compared with normoxia. At baseline (BL; 0.21 fraction of inspired oxygen, FIO2) and at ∼2 (H2) and 4 (H4) h of normobaric hypoxia (0.11 FIO2) in a normobaric hypoxic chamber, 16 healthy participants received electrical musculotendinous stimulation (MTstim) to the MTJ of the left Achilles tendon. The MTstim was delivered as two sets of 50 stimuli while the participant stood on a force plate with their feet together. Tendon-evoked inhibitory reflexes were recorded from the surface electromyogram of the ipsilateral medial gastrocnemius, and center of pressure (CoP) variables were recorded from the force plate. Normobaric hypoxia increased CoP velocity (P ≤ 0.002) but not CoP standard deviation (P ≥ 0.12). Compared with BL, normobaric hypoxia reduced tendon-evoked inhibitory reflex area by 45% at H2 and 53% at H4 (P ≤ 0.002). In contrast, reflex duration was unchanged during hypoxia. The reduced inhibitory feedback from the GTO pathway could likely play a role in the increased postural sway observed during acute exposure to hypoxia.NEW & NOTEWORTHY The Ib pathway arising from the Golgi tendon organ provides inhibitory signals onto motor neuron pools that modifies force and, hence, postural control. Although hypoxia influences standing balance (increases sway), the underlying mechanisms have yet to be unraveled. Our study identified that tendon-evoked inhibition onto a plantar flexor motoneuron pool is reduced by acute exposure to normobaric hypoxia. This reduction of inhibition may contribute to the hypoxia-related increase in postural sway.
The planarian Schmidtea mediterranea is being studied as a model species for regeneration, but the assembly of planarian genomes remains challenging. Here, we report a high-quality haplotype-phased, chromosome-scale genome assembly of the sexual S2 strain of S. mediterranea and high-quality chromosome-scale assemblies of its three close relatives, S. polychroa, S. nova, and S. lugubris. Using hybrid gene annotations and optimized ATAC-seq and ChIP-seq protocols for regulatory element annotation, we provide valuable genome resources for the planarian research community and a first comparative perspective on planarian genome evolution. Our analyses reveal substantial divergence in protein-coding sequences and regulatory regions but considerable conservation within promoter and enhancer annotations. We also find frequent retrotransposon-associated chromosomal inversions and interchromosomal translocations within the genus Schmidtea and, remarkably, independent and nearly complete losses of ancestral metazoan synteny in Schmidtea and two other flatworm groups. Overall, our results suggest that platyhelminth genomes can evolve without syntenic constraints.
In the treatment of atropine poisoning, respiratory assistance and symptomatic support are indicated. Physostigmine salicylate, 1 to 5 mL of a dilution containing 1 mg per 5 mL of saline, should be administered intravenously. Administer the smaller dose in children and administer in not less than 2 minutes. Monitor with ECG. Medication can be repeated every 5 minutes for a total dose of 2 mg in children and every 30 minutes for a total dose of 6 mg in adults.  
The fatal dose of atropine in children may be as low as 10 mg. In an adult, recovery after 1,000 mg of atropine sulfate has been reported. Death is usually due to paralysis of the medullary centers. The fatality rate is less than 1%. If the patient survives 24 hours, they will probably recover.
BACKGROUND: More than 35% of Aboriginal and Torres Strait Islander adults live with cardiovascular disease, diabetes, or chronic kidney disease. There is a pressing need for chronic disease prevention and management among Aboriginal and Torres Strait Islander people in Australia. Therefore, this review aimed to synthesise a decade of contemporary evidence to understand the barriers and enablers of chronic disease prevention and management for Aboriginal and Torres Strait Islander People with a view to developing policy and practice recommendations.
METHODS: We systematically searched for peer-reviewed published articles between January 2014 to March 2023 where the search was performed using subject headings and keywords related to "Aboriginal and Torres Strait Islander peoples," "Chronic Disease," and "Primary Health Care". Quality assessment for all included studies was conducted using the Aboriginal and Torres Strait Islander Quality Appraisal Tool. The data were extracted and summarised using a conventional content analysis approach and applying strength-based approaches.
RESULTS: Database searches identified 1653 articles where 26 met inclusion criteria. Studies varied in quality, primarily reporting on 14 criteria of the Aboriginal and Torres Strait Islander Quality Appraisal Tool. We identified six key domains of enablers and barriers of chronic disease prevention and management programs and implied a range of policy and practice options for improvement. These include culturally acceptable and safe services, patient-provider partnerships, chronic disease workforce, primary health care service attributes, clinical care pathways, and accessibility to primary health care services. This review also identified the need to address social and cultural determinants of health, develop the Aboriginal and Torres Strait Islander and non-Indigenous chronic disease workforce, support multidisciplinary teams through strengthening clinical care pathways, and engage Aboriginal and Torres Strait Islander communities in chronic disease prevention and management program design and delivery.
CONCLUSION: Enabling place-based partnerships to develop contextual evidence-guided strategies that align with community priorities and aspirations, with the provision of funding mechanisms and models of care through policy and practice reforms will strengthen the chronic disease prevention and management program for Aboriginal and Torres Strait Islander people.
In a randomized, double-blind, clinical trial in patients undergoing hip fracture surgery, ARIXTRA 2.5 mg SC once daily was compared to enoxaparin sodium 40 mg SC once daily, which is not approved for use in patients undergoing hip fracture surgery. A total of 1,711 patients were randomized and 1,673 were treated. Patients ranged in age from 17 to 101 years (mean age 77 years) with 25% men and 75% women. Patients were 99% Caucasian, 1% other races. Patients with multiple traumas affecting more than one organ system, serum creatinine level more than 2 mg/dL (180 micromol/L), or platelet count less than 100,000/mm3 were excluded from the trial. ARIXTRA was initiated after surgery in 88% of patients (mean 6 hours) and enoxaparin sodium was initiated after surgery in 74% of patients (mean 18 hours). For both drugs, treatment was continued for 7 ± 2 days. The primary efficacy endpoint, venous thromboembolism (VTE), was a composite of documented deep vein thrombosis (DVT) and/or documented symptomatic pulmonary embolism (PE) reported up to Day 11. The efficacy data are provided in Table 7 and demonstrate that under the conditions of the trial ARIXTRA was associated with a VTE rate of 8.3% compared with a VTE rate of 19.1% for enoxaparin sodium for a relative risk reduction of 56% (95% CI: 39%, 70%; P <0.001). Major bleeding episodes occurred in 2.2% of patients receiving ARIXTRA and 2.3% of enoxaparin sodium patients [see Adverse Reactions (6.1)].

a N = all evaluable hip fracture surgery patients. Evaluable patients were those who were treated and underwent the appropriate surgery (i.e., hip fracture surgery of the upper third of the femur), with an adequate efficacy assessment up to Day 11.

b P value versus enoxaparin sodium <0.001.

c P value versus enoxaparin sodium: NS.